A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a more aggressive form while under active surveillance. The findings, published in the Journal of Urology, suggest that baseline testosterone may serve as a useful clinical marker to better stratify risk and tailor monitoring strategies for patients choosing active surveillance.
This article was originally published on MedicalXpress.com
